First CRISPR-Cas9 Human Trial Lifted from Clinical Hold
The first CRISPR Therapeutics and Vertex collaboration to treat sickle cell disease (SCD), as well as β-thalassemia, was placed on a clinical hold by the FDA earlier this year. The stock for CRISPR Therapeutics and other gene editing companies have been … Continue reading First CRISPR-Cas9 Human Trial Lifted from Clinical Hold